Related Experiment Video
Updated: Jun 20, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Congenital hepatoblastoma: Expanding knowledge, improving outcomes
Francesca Gigola1,2, Francesco Morini2,3, Giorgia Libro1,2
1School of Pediatric Surgery, University of Florence, Florence, Italy.
Insights
Congenital hepatoblastoma (CHB) management is challenging, with outcomes often impacted by mass effect rather than tumor malignancy. CHB prognosis post-birth is not inherently worse, suggesting similar treatment to older children if stable.
Area of Science:
- Pediatric Oncology
- Hepatobiliary Medicine
- Congenital Abnormalities
Background:
- Congenital hepatoblastoma (CHB) is a rare liver tumor with complex clinical management and a historically poor prognosis.
- Existing literature lacks comprehensive data on CHB presentation, diagnosis, and treatment strategies.
- Understanding CHB's unique challenges is crucial for improving patient outcomes.
Purpose of the Study:
- To conduct a literature review on congenital hepatoblastoma (CHB).
- To define CHB presentation, diagnostic approaches, and available treatments.
- To analyze factors influencing CHB outcomes and management.
Main Methods:
- Systematic literature review of congenital hepatoblastoma (CHB) cases.
- Analysis of reported outcomes, focusing on mortality causes.
- Identification of key factors affecting patient survival and prognosis.
Main Results:
- Mortality in CHB is significantly influenced by mass effect (prenatal 22%, perinatal 32%) and oncological factors (46%).
- Postnatal CHB does not appear to confer a worse oncological prognosis compared to hepatoblastoma in older children.
- Stable patients can be managed similarly to older children with hepatoblastoma, following proper staging and treatment.
Conclusions:
- CHB management requires a focus beyond just tumor malignancy, addressing mass effect complications.
- A standardized, data-driven global protocol for CHB is needed for improved outcomes.
- Comprehensive management strategies, informed by extensive data, are essential for advancing CHB care.
Abstract:
Hepatoblastoma (HB) is a rare liver tumour, and its congenital counterpart (CHB) is even less frequent. CHB has a clinically challenging management and a generally perceived worse outcome. This study aims to review the literature on CHB to better define presentation, diagnosis, available treatments and management options. The analysis of outcomes suggests that a significant portion of mortality is unrelated to the malignant nature of the tumour. Key factors influencing overall outcomes were identified: mortality linked to the 'mass effect' during both the prenatal (22%) and perinatal (32%) stages, as well as 'oncological' mortality encompassing tumour and/or treatment-related factors (46%). Overall, after birth, CHB does not seem to confer a worse oncological prognosis per se, and should be managed similarly to older children, if patients are stable enough to undergo proper staging and treatment. A deeper knowledge and better outcomes would come from a large, homogeneous, collection of data possibly allowing a global protocol, focusing on a comprehensive management of CHB.
